Cinacalcet

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Cinacalcet
   1. Pharmacist Assessment Report
   2. Cinacalcet: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Cytotoxicity
   8. Safety Considerations
   9. Disclaimer

---

Pharmacist Assessment Report

Cinacalcet: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Cinacalcet, so there is currently no new predicted indication. The drug’s recorded uses are listed below; none are recorded in the facts for this drug.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	0
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
11885M	Pharmacor Cinacalcet	Tablet 90 mg (as hydrochloride)	Valid

Cytotoxicity

Not applicable. Cinacalcet is not an antineoplastic drug, so this section is omitted.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.

• Disease associations from the knowledge graph (not label text): epilepsy, liver disease, gallbladder disease, hypotensive disorder, hypercalcaemia, nephrocalcinosis, phosphorus metabolism disease and hypophosphataemia. These should be verified against the PI.
• Risks noted in the literature: hypocalcaemia and QT prolongation (PMID 36090548).
• Drug interactions: 100 interactions were recorded. The main ones listed:
  • Major: eliglustat.
  • Moderate: clarithromycin, dexfenfluramine, eluxadoline, glycerol phenylbutyrate, metoclopramide, miconazole.
  • Unclassified: calcitriol, pantoprazole, omeprazole, lansoprazole, morphine, simvastatin, prednisone and others.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---